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Summary
Similar binding sites often imply similar protein-pro-
tein interactions and similar functions; however,
similar binding sitesmay also constitute traps for non-
functional associations. How are similar sites distin-
guished to prevent misassociations? BRCT domains
from breast cancer-susceptibility gene product
BRCA1 and protein 53BP1 have similar structures yet
different binding behaviors with p53 core domain.
53BP1-BRCT domain forms a stable complex with
p53. In contrast, BRCA1-p53 interaction is weak or
other mechanisms operate. To delineate the differ-
ence, we designed 13 BRCA1-BRCTmutants and com-
putationally investigated the structural and stability
changes compared to the experimental p53-53BP1
structure. Interestingly, of the 13, the 2 mutations that
are cancerous and involve nonconserved residues
are those that enforced p53 core domain binding with
BRCA1-BRCT in a way similar to p53-53BP1 binding.
Hence, falling into the ‘‘similarity trap’’ may disrupt
normalBRCA1andp53 functions.Our results illustrate
how this trap is avoided in the native state.
Introduction
The use of genomic sequences to infer and detect pro-
tein function and protein-protein interactions has been
widely accepted as an effective approach to untangle
complex biological phenomena (Marcotte et al., 1999).
In particular, protein-protein interactions are also used
to infer domain-domain interactions (Deng et al., 2002).
Structural conservation in protein-protein interactions
(Ma et al., 2003) distinguishes a protein-binding site
from the exposed protein surface, and, often, structural
similarity may lead to a similar protein-protein interac-
tion and function (Aloy et al., 2003, 2004; Inbar et al.,
2003). These observations are easily understandable
based on the evolution and the physicochemical nature
of protein-protein interactions. Nevertheless, given
these similarities, the question arises: how does nature
*Correspondence: mab@ncifcrf.gov (B.M.), ruthn@ncifcrf.gov (R.N.)distinguish subtle differences, and what happens if
nature’s choice fails?
One example is a domain (BRCT) from the breast can-
cer-susceptibility gene product, BRCA1. BRCA1 relates
to 45% of the families with inherited breast cancers and
90% of the families with inherited breast and ovarian
cancers (Futreal et al., 1994; Miki et al., 1994). BRCA1
encodes a large protein of 1863 amino acids, with
a zinc-finger RING domain N-terminal and tandem
BRCT (BRCA1 C-terminal) domains. BRCT was first
identified in BRCA1 asw95 amino acid tandem repeats
(Koonin et al., 1996) and has been found in many pro-
teins, such as p53-binding protein, 53BP1(Derbyshire
et al., 2002; Joo et al., 2002), the base excision response
scaffold protein, XRCC1, and DNA ligase IV (Sibanda
et al., 2001), many of which appear to participate in
cell-cycle checkpoints or DNA repair in many species
(Glover et al., 2004). BRCT domain of BRCA1 is the tar-
get for a number of cancer-related mutations, and there
is evidence that loss of BRCA1 BRCT domains leads to
tumor formation in mice (Ludwig et al., 2001).
There are data that BRCA1 stimulates p53 transcrip-
tional activity (Chai et al., 1999; Hartman and Ford,
2003; MacLachlan et al., 2002; Navaraj et al., 2005; Zhang
et al., 1998). p53 is a protein that is critical to genome
stability, and missense mutations in p53 are involved in
50% of all human cancers (Hainaut and Hollstein,
2000). BRCA1 has been reported to be able to physically
associate with p53 with two interaction domains: the
central disordered region of BRCA1 interacting with
C-terminal domain of p53 (Mark et al., 2005), and the
BRCT domain of BRCA1 binding with the core domain
of p53 (Chai et al., 1999).
53BP1-p53 interactions have been supported by
biological experiments and observed directly in the
resolved X-ray structure of the 53BP1-p53 complex.
The 53BP1-p53 binding site partially overlaps the p53
DNA-binding site, thus inhibiting the DNA-binding activ-
ities of p53 (Iwabuchi et al., 1994). Although in vitro stud-
ies have shown that p53 cannot bind 53BP1 and DNA
simultaneously (Iwabuchi et al., 1994), there is increasing
evidence that 53BP1 enhances the transcription function
of p53 (Iwabuchi et al., 1998; Glover et al., 2004).
Both 53BP1 and human BRCA1 have two BRCT re-
peats, with high structural similarities even though the
sequence identity is only 19%. Each repeat consists of
four b strands and four a helices, with the exception
that one of the a helices is disordered in the C-terminal
repeat of BRCA1, as shown in Figure 1A. The BRCT
region of 53BP1 was taken from the crystal structure of
the 53BP1-p53 complex (PDB code: 1kzy), and was
superimposed by Swiss-PdbViewer (http://www.expasy.
org/spdbv/) on the crystal structure ofBRCA1 BRCT (PDB
code 1jnx), with an rmsd of 1.44 A˚ for 133 out of 211
BRCA1 Caatoms, including all 8bstrands and 7 of 8ahe-
lices. The N-terminal repeat (repeat 1) of 53BP1 and
BRCA1 can be superimposed with rmsd of 1.38 A˚ (for
69 out of 88 Ca atoms), and the C-terminal repeat (repeat
2) superimposition has an rmsd of 1.25 A˚ (for 60 out of
94 Ca atoms). The sequence identities of repeats 1 and 2
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1812Figure 1. Structure and Sequence Comparisons of 53BP1-BRCT and BRCA1-BRCT
(A) Structures of the BRCT domains of 53BP1 and BRCA1. The regions bound to p53 are shown in yellow. The linker region and LA loop are shown
in red.
(B) Superimposition of the BRCT domain of 53BP1 (green) and BRCA1 (red) to build a model of BRCA1 interacting with p53 (blue).
(C) The domain architectures of BRCA1, 53BP1 and p53.
(D) Sequence alignments of the interface from 53BP1 and BRCA1. The residues that contact p53 are marked by star.are 24% and 17%, respectively. The least conserved
region is the linker between repeats 1 and 2, with a low
10% identity. Except for the linker, the region involved
in 53BP1 bound to p53, including a3A through a4A, has
a striking structural conservation with the corresponding
region of BRCA1, with an rmsd 0.58 A˚ in 23 out of 23 Ca
atoms. The sequence identity of this region (26%) is also
higher than that in the other regions.
Despite the structural conservations, p53 core domain
interacts with the BRCT domains of 53BP1 and BRCA1
proteins to different extents. Using biophysical methods,
including isothermal titration calorimetry, analytical ul-
tracentrifugation, and analytical size-exclusion chroma-
tography, Ekblad et al. (2004) confirmed the p53 core
domain interactions with the BRCT domain of 53BP1
protein, but not with BRCA1 BRCT domain. While it is
possible that these biophysical methods are not sensi-
tive enough, it does imply that, if there is an interaction
between BRCA1 BRCT domain and p53 core domain, it
is very weak, or that other mechanisms are at work.
In order to delineate the difference between the p53
core domain interactions with the BRCT domains of
53BP1 and BRCA1 proteins, we designed 13 BRCA1-
BRCT domain mutants and computationally investi-
gated the stability changes of the simulated complexes
in comparison with the experimentally known p53-
53BP1 structure and the structural changes that takeplace. Four of the mutations we chose are known to be
carcinogenic. Our results revealed that the p53 core
domain interactions with the BRCT domains of 53BP1
and BRCA1 proteins have different charge-charge inter-
action and hydrophobic patterns, leading to decreased
binding abilities of the BRCA1-BRCT domain, despite
the conservation of the BRCT structure in 53BP1 and
BRCA1. Most importantly, it is the two nonconserved
carcinogenic mutants that mostly enforced p53 core
domain binding with BRCA1-BRCT domain in a mode
similar to that of p53-53BP1 binding. Therefore, we pro-
pose that the known binding pattern in p53-53BP1 inter-
action is a ‘‘similarity trap’’ that nature has to avoid in the
p53-BRCA1 interactions. Falling into the ‘‘similarity trap’’
may disrupt the normal functions of both BRCA1 and
p53, and, hence, may be carcinogenic.
Results
In the biophysical analysis of BRCT domain of 53BP1 and
BRCA1, Ekblad et al. (2004) reported that the BRCT
domain of 53BP1 is slightly more stable than that of
BRCA1. Molecular dynamics (MD) simulations were per-
formed to investigate the stability of these two proteins.
The rmsds of the Ca atoms of these two proteins over
time, with respect to the starting minimized structures,
are very close to each other, as shown in Figure 2A,
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1813Figure 2. Ca Rmsds for the BRCT Domain and its Subdomain of 53BP1 and BRCA1, as well as 53BP1-p53 and BRCA1-p53 Complexes
(A) Ca rmsds of 53BP1 (blue) and BRCA1 (red) for the whole BRCT domain including repeat 1, repeat 2 and the linker region.
(B) The Ca rmsds of 53BP1 (blue) and BRCA1 (red) for repeat 1.
(C) The Ca rmsds of 53BP1 (blue) and BRCA1 (red) for the linker region.
(D) The Ca rmsds of 53BP1 (blue) and BRCA1 (red) for repeat 2.
(E) The Ca rmsds of 53BP1-p53 complex (blue) and BRCA1-p53 complex (red).with BRCA1 being slightly larger than 53BP1, which is
consistent with the findings of Ekblad et al. (2004). The
conserved subunit repeat 1 has the closest stability to
53BP1 and BRCA1 (Figure 2B). The more disordered
a2B of BRCA1 contributes to the slightly more flexible
repeat 2 versus the corresponding region of 53BP1, as
shown in Figure 2D. The interrepeat linker is not as
conserved as other regions. 53BP1 with the b-hairpin-
like structure is more stable than BRCA1 with loop LA
followed by the a helix structure at the linker position,
as shown in Figure 2C. Note that the linker region is
one of the binding regions of 53BP1 with p53. Structural
diversity and flexibility at this region may contribute to
a weaker binding of BRCA1 to p53 than to 53BP1.
53BP1-p53 and BRCA1-p53 Complexes
The interaction regions of 53BP1 with p53 include part of
the p53 DNA-binding region and 53BP1 N-terminal
repeat as well as the linker region. Specifically, loops
L2 and L3 and H1 helix of p53 interact with the linker,
a4A and a3A of 53BP1, respectively. One of the DNA-
binding features, H2, is not involved in the 53BP1-p53interaction. A model was built based on the 53BP1-p53
crystal structure and BRCA1 crystal and NMR structures,
as shown in Figure 1B. MD simulations were performed
for both 53BP1-p53 and BRCA1-p53 complexes. In spite
of the relatively small contact area with p53, the interface
of 53BP1-p53 complex is rather stable. The rmsd value of
the interaction region versus the initial structure is
around 2A˚ (blue in Figure 2E). The BRCT structures are
similar in BRCA1 and 53BP1; however, the simulations
suggest that the interaction region of the BRCA1-p53
complex is much less stable (red in Figure 2E).
The interface sequence alignment of BRCA1 and
53BP1 is shown in Figure 1D. 53BP1 has ten residues
that contact p53, including three in a3A, four in a4A,
and three in the linker region. BRCA1 retains eight of
these ten residues to interact with p53, but the two con-
tact positions in the linker region are different because
of the distinct linker structures of 53BP1 and BRCA1.
Among those eight same-position residues, the least
conserved residue is P1849/R1737. 53BP1 proline
1849 interacts with arginine 248 of p53 by favorable
stacking interaction; however, there is a charge conflict
Structure
1814Figure 3. Variations of Distances between Interface Residue Pairs from 53BP1-p53 and BRCA1-p53 Complexes
(A) 53BP1-p53 complex.
(B) BRCA1-p53 complex.
The top plots are residue pairs between p53 and 53BP1/BRCA1 a4 region residues. The bottom plots are residue pairs between p53 and
53BP1/BRCA1 other interface regions.between the corresponding R248-R1737, destabilizing
the interaction of BRCA1 and 53BP1. BRCA1 K1724 in
a3A also has a charge conflict with p53 R181.
In addition to the sequence distinction at the interface,
there are two structural differences that may also affect
the interaction of BRCA1 with p53. The structure be-
tween b3A and a2A is one of them, with a 6 residue
loop in 53BP1, but an 11 residue loop in BRCA1. The lon-
ger loop of BRCA1 reaches p53, providing BRCA1 an
additional possible contact with p53 as compared with
53BP1, including interactions of Arg248-Glu1694 and
Met243-Phe1695.
The linker region structure is also different between
53BP1 and BRCA1. In 53BP1, the linker is composed
of two b strands followed by a loop, whereas BRCA1
has a loop followed by a helix. Due to the structural
difference, corresponding residues in the BRCA1 linker
region cannot interact with p53 as they do in 53BP1.
Instead, in the BRCA1-p53 complex, two other residues,
R1744 and K1750, contact with R248 and Q167 of p53,
respectively. The R1744-R248 charge conflict destabi-
lizes the BRCA1-p53 interface.
In the stable 53BP1-p53 complex, most interacting
residues retain their interaction over time, as shown in
Figure 3A. Three 53BP1 domains bind to p53. These in-terface residue pair distances suggest that the most sta-
ble interaction is a3A and a4A of 53BP1 with the H1 helix
and L3 loop of p53, respectively. The only exception is
that the distance of residue pair R248-L1847 increases
after 9 ns. The least stable interaction is at p53 L2 with
the 53BP1 linker region. There are two contacts in this
region, Gln165-D1861 and Gln167-Q1863. The minimum
distance of both contacts fluctuated, and the contact
was lost after an 8 ns simulation.
The interacting residue distances of the BRCA1-p53
complex over time are shown in Figure 3B. All residue
pairs in a3A fall away from p53 after 8 ns, if not earlier,
as shown at the top. The interaction of BRCA1 a3A with
p53 H1 helix is lost after 2 ns due to the K1724-R181
charge repulsion. The BRCA1 linker-p53 L2 loop contact
region fluctuated during the 10 ns due to the flexibility
of the linker. The most stable residue pair, M243-F1695
in p53 L3 loop and BRCA1 LA loop, does not exist in
53BP1. In short, all three contact regions between
53BP1 and p53 lose contact with p53 in BRCA1 after
a 10 ns simulation, and the only region that retains con-
tact is the LA loop region. By comparing snapshots at
0 and 10 ns (Figure 4, top), it appears that the linker region
has dramatically moved away from the p53 L3 loop to-
ward the p53 H2 helix. There are two possible reasons:
‘‘Similarity Trap’’ in Protein-Protein Interactions
1815Figure 4. Snapshots of the BRCA1-p53 Interface from the Wild-Type, F1695L, and D1733G at 0 and 10 ns
The top panel is the wild-type BRCA1-p53 interface, where the R1744 at the linker region drifts away from crowded LA loop region from 0 to 10 ns.
The middle and bottom panels are mutant F1695L and D1733G, respectively, where the linker region stays stable.the charge repulsion between BRCA1 Arg1744 in the
linker region and p53 Arg248 in the L3 loop, and the
charge attraction between BRCA1 Arg1744 and p53
Glu285. The distance between these two residue pairs
is shown in Figure 3B. The Arg248-Arg1744 distance
increased sharply after 5 ns, while the Glu285-Arg1744
distance started to decrease after 5 ns. It is conceivable,
therefore, that the charge repulsion of the p53 L3 loop
drives the flexible linker loop toward the charge attrac-
tion of the H2 helix.
The reason for the loss of the contact of BRCA1 linker
with the p53 L2 loop can be attributed to the bulky LA
loop. The longer LA loop, including a phenylalanine
residue, of BRCA1 makes the contact region more
crowded, blocking the rotation of the charged residue
in the p53 L3 loop to avoid the positive charge-rich
region of the BRCA1 linker, driving away the flexible
linker region.
BRCA1-p53 Mutations
As discussed in the previous section, we attribute the
weaker interaction of BRCA1 with p53 to the electro-
static repulsion between a3A and a4A, as well as the
linker region of BRCA1 and p53, the steric hindrance of
BRCA1 LA loop, and the flexible loop of the linker of
tandem BRCT. To investigate whether these electro-
static and steric factors can be modulated to allow the
formation of a stable complex, 13 simulations of mutants
in a3A, a4A, LA, and in the linker region were performed.
Among these 13 mutants, mutations of 1724, 1733, 1737,
and 1744 were designed to investigate the effect of elec-trostatic repulsion. Mutations of 1694 and 1695 on the LA
loop, which provides a unique contact region of BRCA1
with p53 compared to 53BP1, are designed for probing
the steric hindrance of the BRCA1 LA loop. A mutant
with two mutations at 1737 and at 1744 was also de-
signed to compare with the single-point mutations at
each of these sites. A total of 4 of these 13 mutants,
F1695L, N1730S, D1733G, and F1734S, are carcino-
genic; these are the only known carcinogenic mutations
of BRCA1 that are in contact with residues with p53 in our
modeled complex. Interestingly, F1695 and D1733 are
not conserved between BRCA1 and 53BP1, while
N1730 and F1734 are conserved. The results of simula-
tions are shown in Figures 5 and 6.
In a3A, there is an electrostatic repulsion between
positively charged residues K1724 and R181 of p53.
Two mutants, K1724E and K1724H, were simulated.
K1724E was expected to stabilize the interface. Since
the corresponding residue in 53BP1 is histidine, K1724H
mutant was also simulated. Figure 5 (top, right) shows
that K1724E stabilizes the interface, while K1724H has
a slightly smaller rmsd value over time than the wild-
type BRCA1 in the first 5 ns; however, after 5 ns, the
rmsd of K1724 increases and is not significantly different
from that of wild-type BRCA1. The RMSF plot (Figure 6)
shows that the residue fluctuation at the interface of
K1724E significantly decreases, especially in the linker
region. This again is not the case for K1724H. This result
is consistent with our expectation that eliminating posi-
tive-charge repulsion in a3A region can stabilize the
BRCA1-p53 interface.
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The top plots are mutants of the LA loop (left) and a3 region (right). The middle plots are mutants of the a4 region. The bottom plots are mutants of
the linker region.At the a4A region, the complexes of D1733R and
D1733G mutants with wild-type p53 were simulated.
Not surprisingly, both mutants stabilize the interface,
as shown in Figure 5 (middle, left). The negatively
charged Asp1733 not only attracts p53 R249, it also at-
tracts BRCA1 R1737 from the linker region. Thus, the
charge repulsion of R249-R1737 is one of the causes
that induce the fluctuation at the linker region. Replacing
the negative aspartic acid by neutral glycine or positively
charged arginine reduces the fluctuation of the linker
region, as shown in Figure 6.
Simulations of mutants N1730S and F1734S were
also performed in the a4A region. Both N1730S and
F1734S are carcinogenic mutations; however, N1730
and F1734 are conserved with 53BP1. F1734 interacts
with p53 M243; thus, not surprisingly, F1734S does not
stabilize the interface. N1730S has a slightly smaller
rmsd value over time than the wild-type BRCA1.Mutants R1737P and R1737E replace arginine by neu-
tral or negatively charged residues to avoid charge con-
flict with p53 Arg248. R1744A and R1744E also mutate
arginine on the linker region to avoid interaction with
E1694 on the LA loop. Interestingly, Figure 5 (bottom,
right) shows that R1737P and R1737E have smaller
rmsd values than the wild-type BRCA1, but the rmsd
value of R1744A is close to the wild-type. In addition,
the RMSF plot suggested that both R1737E and
R1737P decrease the fluctuation at the linker region,
but R1744A increases it, and that R1744E decreases
the fluctuation at the linker region, but increases the
fluctuation in the LA loop. This is not surprising, and
could be explained by the elimination of charge repul-
sion between BRCA1 R1737 and p53 R248, thus stabiliz-
ing the linker region; however, losing the electrostatic
attraction of R1744 and E1694 destabilizes the system
even more. The electrostatic repulsion destabilizes the
‘‘Similarity Trap’’ in Protein-Protein Interactions
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The top plots are mutants of the LA loop (left) and a3 region (right). The middle plots are mutants of the a4 region. The bottom plots are mutants of
the linker region.LA loop. In order to further probe the mutational effects,
we performed simulations for the double-point mutant,
R1737E_R1744E, and compared the results with the
simulations of the corresponding single-point muta-
tions. Both rmsd and RMSF results suggested that the
difference between single-point mutations and double-
point mutations was not significant.
The contact of the LA loop with p53 is unique to
BRCA1, whereas the corresponding loop region of
53BP1 is not long enough for interaction. The BRCA1
LA loop forms the Arg248-Glu1694 and Met243-
Phe1695 interactions with the L3 loop of p53. However,
the existence of these new contacts destabilizes the
contact region of BRCA1 with p53, because Glu1694
on the LA loop not only forms a contact with Arg248 on
the p53 L3 loop, but also attracts Arg1744 at the begin-
ning of the BRCT linker. The repulsion between the two
arginine residues causes a large conformational changeat the interface, including twisting the LA loop and push-
ing the linker loop toward the direction of the p53 H2
helix. The direct consequence of the conformational
change is the loss of the contact between the BRCA1
linker and the p53 L2 loop, thus weakening the interac-
tion of p53 and BRCA1 BRCT.
To test whether the LA loop is responsible for the flex-
ibility of BRCA1-p53 interface, simulations on two muta-
tions, E1694K and F1695L, were performed in the LA
loop. As shown in Figure 5, the E1694K avoided the
two arginine residue situation, p53 R248 and BRCA1
R1744, stabilizing the linker loop during the first 6 ns;
however, the repulsion of the lysine and linker region,
arginine R1744, finally caused structural fluctuation of
the linker region, as shown in the RMSF plot (Figure 6),
increasing the rmsd of E1694K significantly after 6 ns.
Although F1695L is not directly connected to the interac-
tion at the linker region, leucine is less likely to cause
Structure
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can rotate to form an Arg-Asn hydrogen bond instead of
interacting with Glu1694. Therefore, repulsion of Arg248-
Arg1744 is again avoided, and the linker is stabilized.
The binding energy differences and average rmsd of
the complex interface were calculated for each mutant
and are listed in Table 1. The more negative theDDG, the
stronger the BRCA1-p53 binding it implies; also, smaller
rmsd values of the complex interface suggest a more
stable interface. Compared to wild-type BRCA1, mu-
tants F1695L and D1733G have the most negative DDG,
suggesting stronger binding with p53 than the wild-type
BRCA1 in this orientation. In addition, these two mutants
have the lowest average rmsd values. Interestingly,
according to the National Human Genome Research In-
stitute breast cancer mutation database, these two mu-
tants are the only cancer-related mutants among all the
mutants simulated. Considering that the binding energy
of F1695L mutants with p53 is more negative, and the
average rmsd value is lower, than that of D1733G, we
predict that, among these 13 mutants, F1695L could be
the mutant candidate to most stabilize the interface of
BRCA1-p53 complex in the conformation similar to
that of the 53BP1-p53 complex.
Discussion
BRCA1 has been observed to associate with p53 in var-
ious cell functions. However, the interaction between the
BRCA1 BRCT domain and the p53 core domain has been
suggested to be weak, and the structure of the complex
has yet to be solved. On the other hand, the complex
structure of 53BP1, which has remarkable similarity to
the BRCT tandem repeat in BRCA1, has been solved in
complex with p53. Given the structural conservation, it
is plausible that, should the BRCA1 interact with p53,
the interaction would mimic that of 53BP1. However, our
simulations suggest that an interaction between BRCA1
BRCT domain and the p53 core domain in a binding
mode similar to that of the 53BP1 is not favorable for
BRCA1. A potential reason why this interface is dis-
favored by nature is that this binding mode blocks the
interaction of p53 with DNA. Alternatively, the interaction
between BRCA1 and p53 may take place in a different
Table 1. Comparison of the Binding Energy and Interface Average
Ca Rmsd for BRCA1 Mutants Bound to p53
Binding Energy, DDG
(kcal/mol) Average Rmsd (A˚)
WT 0.00 2.63
E1694K 20.32 2.29
F1695L 220.32 1.74
K1724E 22.04 2.23
K1724H 17.42 2.31
D1733R 23.65 1.97
D1733G 217.67 1.98
N1730S 1.47 2.19
F1734S 13.26 2.51
R1737P 13.89 2.20
R1744A 27.27 2.53
R1737E 18.32 2.10
R1744E 22.78 2.42
R1737E_R1744E 8.79 2.34
Bold text indicates mutants with the most negative binding energy.binding mode. One of the possible binding modes of
p53 to BRCA1 is to the second BRCT domain (Chai
et al., 1999). In the literature, there are two experiments
with different results related to p53 binding. The first ob-
served p53 binding by biological gel shift with the second
repeat only (Chai et al., 1999); on the other hand, the sec-
ond biophysical analysis observed no binding by using
two repeats (Ekblad et al., 2004). Thus it is possible that
functional BRCA1 has a large conformational change
to expose the second repeat binding site. On the p53
side, it is also possible that binding occurs on the phos-
phorylated site, rather than in the DNA-binding region.
We are investigating these potential alternative binding
modes.
If the BRCA1-BRCT domain interacts with p53 in
a different mode, it has to be substantially stronger
than the 53BP1-p53 binding mode to shift the equilibrium
toward this mode and avoid a ‘‘similarity trap.’’ However,
we can not exclude the possibility that BRCA1 BRCT
domain has no interaction with p53 core domain at all.
In both cases, the nonconserved cancer-related muta-
tions appear to lead BRCA1 and p53 to bind in a
53BP1-p53 binding mode, blocking the binding of p53
to the DNA and potentially causing cancer development.
Remarkably, N1730S and F1734S are also carcinogenic
mutants; however, unlike F1695 and D1733, both N1730
and F1734 are residues conserved between BRCA1 and
53BP1. Interestingly, our results indicate that the N1730S
and F1734S mutations do not shift the equilibrium toward
a 53BP1-p53 binding mode. This observation is in agree-
mentwithstatistical observationsofsequence variation in
ligand-binding site (Magliery and Regan, 2005, BMC, Bio-
informatics, abstract). Sequence analysis of four protein
families has indicated that it is the variant, rather than
the conserved residues, which may determine the binding
sites. Thus, a ‘‘similarity trap’’ mechanism could be carci-
nogenic; but not every carcinogenic mutant necessarily
follows such a dysfunctional mechanism.
To our knowledge, 53BP1 is not reported to interact
with p53 in other domains. On the other hand, the BRCA1
central region has been reported to interact with p53
C-terminal domain (Mark et al., 2005), which could hinder
the 53BP1-like binding of the BRCT with carcinogenic
mutations, competing with it. However, it is not clear
how strong such a binding of the BRCA1 central region
with the p53 C-terminal domain is.
F1695L is the mutant that most stabilizes the complex
among these 13 mutants, probably since phenylalanine
prevents the movement of Arg248. If phenylalanine is
replaced by a hydrophobic yet more flexible residue, it
allows the Arg248 side chain to rotate away from
Arg1744, thus preventing the drifting of the linker resi-
dues, retaining the contact of the linker with the L3
loop. F1695L is a breast cancer-related mutation.
Thus, the prediction that the F1695L mutation stabilizes
the BRCA1-p53 complex may provide some insight into
the association and its role in breast cancer. D1733G,
another cancer-associated mutant, also stabilizes the
complex interface to some degree, because it avoids at-
tracting a positively charged residue from the BRCA1
loop region, thus preventing accumulation of positive
charge around the p53 L3 loop. Taken together, by sta-
bilizing the unwanted interactions, the p53 binds BRCA1
in a way similar to the p53-53BP1 binding pattern, thus
‘‘Similarity Trap’’ in Protein-Protein Interactions
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genic mutants strongly disturbed the native functions.
Apart from the proposed mechanism, the F1695L
mutation may also disrupt another important binding
with BACH1 (Joo et al., 2002). The BRCA1 BRCT domain
has recently been identified as phospho-protein-bind-
ing domain, with evidence of its interaction with phos-
phorylated DNA helicase BACH1, as well as CtBP inter-
acting protein (Clapperton et al., 2004, Manke et al.,
2003, Varma et al., 2005, Williams et al., 2004, Yu et al.,
2003). The interaction between the BRCA1 BRCT
domain and BACH1 has been implicated to be cell-cycle
regulated, and is required for G2/M cell-cycle checkpoint
control in response to DNA damage (Manke et al., 2003,
Yu et al., 2003). The interaction sites are different from
the interaction sites we explored for BRCA1-p53 inter-
action. It has been found that the F1695L mutation can
reduce the interaction between BRCA1 BRCT with
BACH1. Based on this discovery, Joo et al. (2002) ini-
tially hypothesized that the LA loop is one of the interac-
tion regions with BACH1, but the solved structure of
BRCA1-BACH1 complex shows that the LA loop is not
involved in this interaction, lending support to our pro-
posed mechanism. Our results imply a possible expla-
nation to the observation that BRCT-p53 interaction
may regulate the BRCT-BACH1 interactions. The BRCT
domain can not bind simultaneously to both p53 core
domain at this binding site and phosphoprotein.
BRCA1-BACH1 interaction is only detected in S and
G2/M phase, whereas BRCA1-p53 interaction is sug-
gested to take place in G1 phase. It is possible that
BRCA1 initially participates in stabilization and accumu-
lation of p53 protein by forming a transient complex with
p53, and then is free to interact with BACH1. With the
cancer-related mutation, F1695L, the unregulated
‘‘similarity trapped’’ BRCA1-p53 binding prevents the
BRCA1 interaction with BACH1.
Conclusions
Our MD simulations suggest that the interaction of
BRCA1 BRCT domain with p53 core domain is weaker
than that of 53BP1 in a similar binding mode, despite
their conserved structures. The weaker interaction of
BRCA1-p53 is attributed to the linker region structure,
the longer loop at the interface, as well as the electro-
static repulsion at the BRCA1-p53 interface. A total of
13 BRCA1-BRCT domain mutants were designed, and
the stabilities of their interactions with p53 and structural
effects were tested by MD simulation. Of the 13, 4 mu-
tants are carcinogenic; these are the only known carci-
nogenic mutations of BRCA1 in contact with p53 when
modeled in a 53BP1-like binding mode. Two of these
four, N1730 and F1734, are conserved between BRCA1
and 53BP1, and two, F1695 and D1733, are not con-
served. Interestingly, it is the two nonconserved carcino-
genic mutants, F1695L and D1733G, that enforced the
binding of p53 core domain with BRCA1-BRCT domain
in a way similar to that with 53BP1 protein. Therefore,
we propose that the known binding pattern in p53-
53BP1 interaction is a ‘‘similarity trap’’ that nature has
to avoid in the p53-BRCA1 interactions. Falling into the
‘‘similarity trap’’ might disrupt normal functions of both
BRCA1 and p53, and is carcinogenic. Here, we have
analyzed the respective interfaces to obtain an insightinto such a trap that is avoided in the native functional
protein state.
Experimental Procedures
Computational Methods
Modeling
Currently, there is no resolved structure to provide any atomic
details of the interaction of BRCA1 with p53. However, the complex
structure of p53 with 53BP1, whose BRCT domain is strikingly sim-
ilar to BRCA1 BRCT domain, has been solved (Derbyshire et al.,
2002; Joo et al., 2002). Here, we build a model of BRCA1-p53 com-
plex based on the crystal structure of 53BP1 BRCT domain bound to
p53 core domain (PDB code: 1kzy) and the crystal structure of
BRCA1 BRCT domain (PDB code: 1jnx), as well as the NMR struc-
ture of the C-terminal repeat of BRCA1 BRCT domain (PDB code:
1oqa). Specifically, we performed structural alignment of 53BP1
BRCT domain and BRCA1 BRCT domain, followed by replacing
53BP1 in the 53BP1-p53 complex by BRCA1. Because four residues
are missing in the BRCA1 crystal structure, but three of these are
available in the NMR structure of the C-terminal repeat of BRCA1
BRCT domain, the BRCA1 crystal structure was aligned with the
NMR structure of its C-terminal repeat to fill the coordinates of miss-
ing residues. The fourth missing residue was modeled using
CHARMM (Brooks et al., 1983). The four missing residues underwent
20 ps dynamics after energy minimization for 500 steps, with the rest
of the protein fixed. The starting structures of the BRCA1-p53 com-
plex with mutations were built from the wild-type model, with all of
the backbone atoms superimposed on the corresponding atoms
of the wild-type structure. The side chains were generated by
CHARMM and underwent 500 steps of energy minimization, with
the rest of the protein fixed to remove any steric conflicts before
the MD simulations were performed.
MD Simulations
MD simulations have been performed with CHARMM 22 (MacKerell
et al., 1998) force field with CHARMM. The starting structure of the
53BP1 BRCT domain bound to p53 core domain was constructed
from the crystal structure solved by Joo et al. (2002) (PDB code
1kzy). The homology structure of the complex of BRCA1 BRCT
region with p53 was constructed, based on the crystal structure of
53BP1-p53 and the crystal and NMR structure of the BRCT region
of BRCA1 (Gaiser et al., 2004, Williams et al., 2001) (PDB code 1jnx
and 1oqa). The 53BP1 monomer structure is extracted from the
53BP1-p53 complex. The structures of 27 residues are missing in
53BP1. Missing residues were added as random coils, and 20 ps
dynamics were performed after energy minimization for 500 steps,
with the rest of the protein fixed. All models are solvated in
a TIP3P water box with a minimum distance of 10 A˚ from the edge
of the box to any protein atom. The charges of the system were neu-
tralized by adding chloride or sodium ions. To eliminate residual
unfavorable interactions between the solvent and the protein, the
solvated systems were first minimized for 500 steps, with the protein
restrained, followed by another 500 steps of minimization for the
whole system by using the steepest decent algorithm. After 20 ps
equilibration with the NVT ensemble, the production simulations
were performed for 10 ns with the NPT ensemble at a temperature
of 300K. During the production simulation, the time step was 2 fs,
with a SHAKE constraint on all bonds containing hydrogen atoms,
and the nonbonded cutoff was 12 A˚. Structures were saved every
2 ps. For p53-involved simulations, the distances between the zinc
atom and its coordinate residues, including three Cys and one His
residues, were constrained within 0.2 A˚ of the crystal distance by
the nuclear overhauser enhancement module implemented in
CHARMM. The simulation results were analyzed with CHARMM.
The contact residue pairs of 53BP1-p53 are defined as residue pairs
with minimum atom distance less that 4 A˚. For the BRCA1-p53 inter-
action, the corresponding pairs to 53BP1-p53 were analyzed as well
as residue pairs with minimum atom distance less than 4 A˚.
Free Energy Calculations
The interaction between BRCA1 and p53 were calculated as follows:
DGðBRCA1-p53Þ = EMMðBRCA1-p53Þ + GsolvðBRCA1-p53Þ
2 ½EMMðBRCA1Þ + GsolvðBRCA1Þ + EMMðp53Þ + Gsolvðp53Þ; (1)
Structure
1820where EMM is the molecular mechanical energy of the system con-
sisting of all components in the CHARMM potential energy function,
as shown Equation 2:
EMM = Ebond + Eangle + EUrey-Bradley + Edihedral + Eimproper + EVDWalls + Eelec:
(2)
Gsolv could be written as two terms, as shown in equation (3).
Gsolv = Gelec + Gne: (3)
The electrostatic contribution to the solvation energy, Gelec, were
calculated with the generalized Born with the molecular volume
(GBMV) method (Lee et al., 2003). The most accurate grid-based
module was used. The nonelectronic term, Gne, was calculated
through solvent-accessible surface area calculations.
Energy calculations (DG[BRCA1-p53]) were performed on the 500
structures extracted from the simulation trajectories at 20 ps time
intervals during the 10 ns simulations. Statistical analysis was per-
formed by obtaining the overall averages from these 500 structures.
The contribution of mutations to the binding energy of BRCA1 and
p53 were evaluated using the following equation:
DDGðBRCA1mut-p53Þ =DGðBRCA1mut-p53Þ
2DGðBRCA1WT-p53Þ (4)
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